AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8701596 — intervention group
Group type: COMPARATOR
Intervention: Conventional trivalent influenza vaccine, Fluogen (Parke‐Davis)
Number of subjects: 88
Study 2225407 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IMA grafting (group 1)
Number of subjects: 1063
Study 2225407 — intervention group
Group type: COMPARATOR
Intervention: Multiple IMA grafting (group 2)
Number of subjects: 1063
Study 27373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 3 X 10 mg daily or 3 X 20 mg daily
Number of subjects: 63
Study 27373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31879752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 250
Study 31879752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 250
Study 31879752 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleo diet
Number of subjects: 250
Study 31258920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (three times a week) with clarithromycin, rifampicin, and ethambutol for 1 year
Number of subjects: 140
Study 31258920 — intervention group
Group type: COMPARATOR
Intervention: Daily treatment with clarithromycin, rifampicin, and ethambutol for 1 year
Number of subjects: 140
Study 31258920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment
Number of subjects: 140
Study 28987246 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 854
Study 28987246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 854
Study 28987246 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 854
Study 28987246 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 854
Study 28987246 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 854
Study 26926538 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.01 mg/kg once daily) as adjunctive therapy after shock wave lithotripsy
Number of subjects: 120
Study 26926538 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol only
Number of subjects: 120
Study 24419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 985
Study 24419109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Number of subjects: 985
Study 24419109 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (completion of therapy)
Number of subjects: 985
Study 22664978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 10 mL
Number of subjects: 185
Study 22664978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 20 mL
Number of subjects: 185
Study 22664978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375% 40 mL
Number of subjects: 185
Study 22664978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% 20 mL
Number of subjects: 185
Study 22664978 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75% 5 mL
Number of subjects: 185
Study 19619331 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil or placebo
Number of subjects: 654
Study 19619331 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide)
Number of subjects: 654
Study 17719358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of the future
Number of subjects: 72
Study 17719358 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical limitations
Number of subjects: 72
Study 17719358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 72
Study 17719358 — intervention group
Group type: EXPERIMENTAL
Intervention: Problems with family or friends due to cancer
Number of subjects: 72
Study 15232663 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day)
Number of subjects: 12
Study 15232663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12442238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous opiate analgesia
Number of subjects: 205
Study 12442238 — intervention group
Group type: COMPARATOR
Intervention: Baseline (before analgesia)
Number of subjects: 205
Study 9660383 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5 to 25 mg/d) with step-up to atenolol (25.0 to 50.0 mg/d) or reserpine (0.05 to 0.10 mg/d)
Number of subjects: 4736
Study 9660383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 8704425 — intervention group
Group type: COMPARATOR
Intervention: Qi stagnation type of CHD
Number of subjects: 46
Study 8704425 — intervention group
Group type: COMPARATOR
Intervention: Blood stasis type of CHD
Number of subjects: 46
Study 30025991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Number of subjects: 13
Study 30025991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27039945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (rosuvastatin 10 mg/day, candesartan 16 mg/day, hydrochlorothiazide 12.5 mg/day)
Number of subjects: 12705
Study 27039945 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 12705
Study 23816321 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP without Ca
Number of subjects: 100
Study 23816321 — intervention group
Group type: COMPARATOR
Intervention: MNP with Ca
Number of subjects: 100
Study 23303315 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-iron (30 mg)
Number of subjects: 18775
Study 23303315 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, iron, and 13 additional vitamins and minerals
Number of subjects: 18775
Study 23303315 — intervention group
Group type: COMPARATOR
Intervention: Daily folic acid (400 μg)
Number of subjects: 18775
Study 19833619 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 43
Study 19833619 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 43
Study 18958980 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility for misfortune
Number of subjects: 0
Study 16574482 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 220
Study 16574482 — intervention group
Group type: COMPARATOR
Intervention: Stretching (Control)
Number of subjects: 220
Study 12534314 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 0
Study 12534314 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release preparation of VPA
Number of subjects: 0
Study 10921541 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (0.02 approximately 0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 19
Study 10921541 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 19
Study 8729154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 225
Study 8729154 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDIs)
Number of subjects: 225
Study 1314910 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 837
Study 1314910 — intervention group
Group type: COMPARATOR
Intervention: No radiation therapy (Control)
Number of subjects: 837
Study 3905713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 40
Study 3905713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30461644 — intervention group
Group type: EXPERIMENTAL
Intervention: Single B-mode ultrasound guidance
Number of subjects: 300
Study 30461644 — intervention group
Group type: COMPARATOR
Intervention: Color Doppler ultrasound guidance
Number of subjects: 300
Study 26469812 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix (CMX) + coronally advanced flap (CAF)
Number of subjects: 17
Study 26469812 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) + coronally advanced flap (CAF)
Number of subjects: 17
Study 26084342 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 202
Study 26084342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic epilepsy
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic epilepsy
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized seizures
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial seizures
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple partial seizures
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex partial seizures
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed seizures
Number of subjects: 3066
Study 22948127 — intervention group
Group type: COMPARATOR
Intervention: Rural population
Number of subjects: 3066
Study 22948127 — intervention group
Group type: COMPARATOR
Intervention: Illiterate group
Number of subjects: 3066
Study 22948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and teenagers
Number of subjects: 3066
Study 20223500 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 20223500 — intervention group
Group type: COMPARATOR
Intervention: TNF-alpha inhibitors
Number of subjects: 0
Study 20223500 — intervention group
Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 0
Study 20223500 — intervention group
Group type: COMPARATOR
Intervention: Other biologic agents
Number of subjects: 0
Study 18476421 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqi Fuzheng Decoction (HQFZD)
Number of subjects: 84
Study 18476421 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir (Control group A)
Number of subjects: 84
Study 18476421 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir plus interferon (Control group B)
Number of subjects: 84
Study 16756149 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and long acting beta2-agonists
Number of subjects: 91
Study 16756149 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (Control group)
Number of subjects: 91
Study 16295138 — intervention group
Group type: EXPERIMENTAL
Intervention: Active teaching method using the Kardorff-Schnelle-Parker skin model (10-min demonstration on day 0 and day 14)
Number of subjects: 30
Study 16295138 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving verbal instructions of the same duration
Number of subjects: 30
Study 10641586 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0
Study 10641586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 10641586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8898504 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and attitudes (cognitive factors)
Number of subjects: 122
Study 8898504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive factors
Number of subjects: 122
Study 8898504 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory
Number of subjects: 122
Study 1797953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of Andrographis paniculata
Number of subjects: 152
Study 1797953 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day of Andrographis paniculata
Number of subjects: 152
Study 1797953 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 152
Study 6418561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 17
Study 6418561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 17
Study 6418561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus sodium cromoglycate
Number of subjects: 17
Study 6418561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29522174 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg
Number of subjects: 1717
Study 29522174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study 27459266 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV (live‐attenuated, tetravalent dengue vaccine)
Number of subjects: 0
Study 27459266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24099735 — intervention group
Group type: EXPERIMENTAL
Intervention: D4D prosocial behavior incentive (monetary donation to WFP based on ALT decrease)
Number of subjects: 25
Study 24099735 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary and exercise intervention alone
Number of subjects: 25
Study 23767865 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia extracts (500 mg/day)
Number of subjects: 29
Study 23767865 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia leaves extract
Number of subjects: 29
Study 23767865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 20838237 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric counseling (Group A)
Number of subjects: 211
Study 20838237 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical monitoring (Group B)
Number of subjects: 211
Study 17765214 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory secondary task during the 'Eyes' pictorial test of Theory of Mind
Number of subjects: 0
Study 17765214 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal 'Stories' task with concurrent executive function tasks
Number of subjects: 0
Study 16794882 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual approach in the care of people with dementia; specific details on dosage and duration not available.
Number of subjects: 0
Study 16794882 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual everyday situations for residents; specific details on dosage and duration not available.
Number of subjects: 0
Study 16794882 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication between nurses and residents; specific details on dosage and duration not available.
Number of subjects: 0
Study 16794882 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal attention from nurses; specific details on dosage and duration not available.
Number of subjects: 0
Study 15285076 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy
Number of subjects: 0
Study 15285076 — intervention group
Group type: COMPARATOR
Intervention: Carotid Angioplasty with primary stenting and cerebral protection
Number of subjects: 0
Study 11189683 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination and blood test for prostate-specific antigen (PSA) for prostate cancer
Number of subjects: 148000
Study 11189683 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroanterior view chest X‐ray for lung cancer
Number of subjects: 148000
Study 11189683 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐cm flexible sigmoidoscopy for colorectal cancer
Number of subjects: 148000
Study 11189683 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test for CA125 tumor marker and transvaginal ultrasound for ovarian cancer
Number of subjects: 148000
Study 11189683 — intervention group
Group type: COMPARATOR
Intervention: Usual care for control group
Number of subjects: 148000
Study 9314997 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-125 mL of 60% nonionic contrast material pushed with 50 mL of saline
Number of subjects: 75
Study 9314997 — intervention group
Group type: COMPARATOR
Intervention: 125 mL of 60% nonionic contrast material administered alone
Number of subjects: 75
Study 8499429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 25
Study 8499429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 551
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than college education
Number of subjects: 551
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 551
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol
Number of subjects: 551
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body mass index
Number of subjects: 551
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, lower education, lower body mass index, baseline electrocardiographic abnormalities
Number of subjects: 551
Study 3303916 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, lower education, history of cardiovascular event, smoking
Number of subjects: 551
Study 3303916 — intervention group
Group type: COMPARATOR
Intervention: Sex
Number of subjects: 551
Study 28597693 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy + mental practice
Number of subjects: 14
Study 28597693 — intervention group
Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy
Number of subjects: 14
Study 26514341 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression surgery between two and three months after onset (group I)
Number of subjects: 41
Study 26514341 — intervention group
Group type: COMPARATOR
Intervention: Follow-up observation (group III)
Number of subjects: 41
Study 25218311 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel bisulfate
Number of subjects: 90
Study 25218311 — intervention group
Group type: COMPARATOR
Intervention: Branded clopidogrel bisulfate
Number of subjects: 90
Study 25218311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 90
Study 22536843 — intervention group
Group type: EXPERIMENTAL
Intervention: STAN® (index group)
Number of subjects: 5681
Study 22536843 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography (control group)
Number of subjects: 5681
Study 20532167 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-assisted iCBT
Number of subjects: 150
Study 20532167 — intervention group
Group type: EXPERIMENTAL
Intervention: Technician-assisted iCBT
Number of subjects: 150
Study 20532167 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 150
Study 18612259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention workshop for coaches
Number of subjects: 0
Study 18612259 — intervention group
Group type: COMPARATOR
Intervention: Control workshop for coaches
Number of subjects: 0
Study 15836683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Infraclavicular Plexus Block (VIP)
Number of subjects: 30
Study 15836683 — intervention group
Group type: COMPARATOR
Intervention: High Axillary Plexus Block (HAP)
Number of subjects: 30
Study 12415196 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/LEV, weekly, 12 months
Number of subjects: 180
Study 12415196 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/FA, days 1‐5, every 4 weeks, 12 months
Number of subjects: 180
Study 12415196 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/FA, days 1‐5, every 4 weeks, 6 months
Number of subjects: 180
Study 10503821 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-metronidazole-clarithromycin treatment
Number of subjects: 0
Study 10503821 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole-resistance
Number of subjects: 0
Study 10503821 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole addition
Number of subjects: 0
Study 8565748 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 million units of interferon-alpha 2b per week for 24 weeks
Number of subjects: 24
Study 8565748 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5-30 million units of interferon-alpha 2b per week for 24 weeks
Number of subjects: 24
Study 8565748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon therapy
Number of subjects: 24
Study 2008690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid occlusive bandage (DuoDERM ConvaTec, Squibb)
Number of subjects: 38
Study 2008690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study 6761637 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin therapy
Number of subjects: 47
Study 6761637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 31278785 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (r‐ATG/EVR)
Number of subjects: 171
Study 31278785 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate (r‐ATG/MPS)
Number of subjects: 171
Study 28454511 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression
Number of subjects: 115
Study 28454511 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 115
Study 27744141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg every 4 weeks plus DMARDs)
Number of subjects: 357
Study 27744141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 4 weeks plus DMARDs)
Number of subjects: 357
Study 25623430 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen carbohydrate 125-guided therapy
Number of subjects: 383
Study 25623430 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 383
Study 21777054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat cereal (RTEC) consumed instead of normal evening snack for 6 weeks
Number of subjects: 70
Study 21777054 — intervention group
Group type: COMPARATOR
Intervention: Normal evening snack (control group)
Number of subjects: 70
Study 20456867 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrival index for cortisol
Number of subjects: 88
Study 20456867 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrival index for alpha-amylase
Number of subjects: 88
Study 20456867 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrival index for cortisol and alpha-amylase
Number of subjects: 88
Study 20456867 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of difference in cortisol and alpha-amylase between arrival and 1h after arrival
Number of subjects: 88
Study 20456867 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anxiety
Number of subjects: 88
Study 18072367 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promotion intervention
Number of subjects: 61